1. Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG. Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy. ACS Nano 2022; 16: 8729-8750.
2.
Aras A, Khokhar AR, Qureshi MZ, Silva MF, Sobczak-Kupiec A, Pineda EA, Hechenleitner AA, Farooqi AA. Targeting cancer with nano-bullets: curcumin, EGCG, resveratrol and quercetin on flying carpets. Asian Pac J Cancer Prev 2014; 15: 3865-3871.
3.
Attar R, Panah T, Romero MA, Yulaevna IM, Gazouli M, Berardi R, Wieczorek E, Farooqi AA. Overview of the signaling pathways involved in metastasis: An intriguing story-tale of the metastatic journey of ovarian cancer cells. Cell Mol Biol (Noisy-le-grand) 2021; 67: 212-223.
4.
Farhan M, Malik A, Ullah MF, Afaq S, Faisal M, Farooqi AA, Biersack B, Schobert R, Ahmad A. Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs. Int J Mol Sci 2019; 20: 800.
5.
Farooqi AA, Li Y, Sarkar FH. The biological complexity of RKIP signaling in human cancers. Exp Mol Med 2015; 47: e185.
6.
Farooqi AA, Nayyab S, Martinelli C, Berardi R, Katifelis H, Gazouli M,Cho WC. Regulation of Hippo, TGF-b/SMAD, Wnt/b-catenin, JAK/STAT, and NOTCH by long non-coding RNAs in pancreatic cancer. Front Oncol 2021; 11: 657965.
7.
Farooqi AA, Qureshi MZ, Coskunpinar E, Naqvi SK, Yaylim I, Ismail M. MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis. Asian Pac J Cancer Prev 2014; 15: 1909-1912.
8.
Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, Farooqi AA, Papadia A, Panici PB. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev 2015; 16: 3635-3638.
9.
Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Benedetti Panici P. PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? Geburtshilfe Frauenheilkd 2017; 77: 1095-1103.
10.
Gasparri ML, Besharat ZM, Farooqi AA, Khalid S, Taghavi K, Besharat RA, Sabato C, Papadia A, Panici PB, Mueller MD, Ferretti E. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. J Cancer Res Clin Oncol 2018; 144: 2313-2318.
11.
Gooding M, Malhotra M, McCarthy DJ, Godinho BM, Cryan JF, Darcy R, O’Driscoll CM. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis. Eur J Pharm Sci 2015; 71: 80-92.
12.
Han M, Xing H, Chen L, Cui M, Zhang Y, Qi L, Jin M, Yang Y, Gao C,Gao Z, Xing X, Huang W. Efficient antiglioblastoma therapy in mice through doxorubicin-loaded nanomicelles modified using a novel brain-targeted RVG-15 peptide. J Drug Target 2021; 29: 1016-1028.
13.
He C, Ding H, Chen J, Ding Y, Yang R, Hu C, An Y, Liu D, Liu P, Tang Q, Zhang Z. Immunogenic cell death induced by chemoradiotherapy of novel pH-Sensitive cargo-loaded polymersomes in glioblastoma. Int J Nanomedicine 2021; 16: 7123-7135.
14.
He C, Zhang Z, Ding Y, Xue K, Wang X, Yang R, An Y, Liu D, Hu C, Tang Q. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. J Nanobiotechnology 2021; 19: 29.
15.
He W, Li X, Morsch M, Ismail M, Liu Y, Rehman FU, Zhang D, Wang Y, Zheng M, Chung R, Zou Y, Shi B. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano 2022; 16: 6293-6308.
16.
Katifelis H, Nikou MP, Mukha I, Vityuk N, Lagopati N, Piperi C, Farooqi AA, Pippa N, Efstathopoulos EP, Gazouli M. Ag/Au bimetallic nanoparticles trigger different cell death pathways and affect damage associated molecular pattern release in human cell lines. Cancers (Basel) 2022; 14: 1546.
17.
Li X, Xu H, Li C, Qiao G, Farooqi AA, Gedanken A, Liu X, Lin X. Zinc-doped copper oxide nanocomposites inhibit the growth of pancreatic cancer by inducing autophagy through AMPK/mTOR pathway. Front Pharmacol 2019; 10: 319.
18.
Lin X, Khalid S, Qureshi MZ, Attar R, Yaylim I, Ucak I, Yaqub A, Fayyaz S, Farooqi AA, Ismail M. VEGF mediated signaling in oral cancer. Cell Mol Biol (Noisy-le-grand) 2016; 62: 64-68.
19.
Liu PF, Farooqi AA, Peng SY, Yu TJ, Dahms HU, Lee CH, Tang JY, Wang SC, Shu CW, Chang HW. Regulatory effects of noncoding RNAs on the interplay of oxidative stress and autophagy in cancer malignancy and therapy. Semin Cancer Biol 2022; 83: 269-282.
20.
Liu S, Liu J, Li H, Mao K, Wang H, Meng X, Wang J, Wu C, Chen H, Wang X, Cong X, Hou Y, Wang Y, Wang M, Yang YG, Sun T. An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy. Biomaterials 2022; 287: 121645.
21.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. Erratum in: Acta Neuropathol 2007; 114: 547.
22.
Mao X, Calero-Pérez P, Montpeyó D, Bruna J, Yuste VJ, Candiota AP,Lorenzo J, Novio F, Ruiz-Molina D. Intranasal administration of catechol-based Pt(IV) coordination polymer nanoparticles for glioblastoma therapy. Nanomaterials (Basel) 2022; 12: 1221.
23.
Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO. Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncol Rev 2017; 11: 332.
24.
Nogueira DR, Scheeren LE, Macedo LB, Marcolino AI, Pilar Vinardell M, Mitjans M, Rosa Infante M, Farooqi AA, Rolim CM. Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy. Amino Acids 2016; 48: 157-168.
25.
Ou A, Ott M, Fang D, Heimberger AB. The role and therapeutic targeting of JAK/STAT signaling in glioblastoma. Cancers (Basel) 2021; 13: 437.
26.
Ouyang J, Jiang Y, Deng C, Zhong Z, Lan Q. Doxorubicin delivered via ApoE-directed reduction-sensitive polymersomes potently inhibit orthotopic human glioblastoma xenografts in nude mice. Int J Nanomedicine 2021; 16: 4105-4115.
27.
Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin 1998; 48: 331-360, 321.
28.
Qiao G, Xu H, Li C, Li X, Farooqi AA, Zhao Y, Liu X, Liu M, Stagos D, Lin X. Granulin a synergizes with cisplatin to inhibit the growth of human hepatocellular carcinoma. Int J Mol Sci 2018; 19: 3060.
29.
Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994; 54: 4299-4303.
30.
Renziehausen A, Tsiailanis AD, Perryman R, Stylos EK, Chatzigiannis C, O’Neill K, Crook T, Tzakos AG, Syed N. Encapsulation of temozolomide in a calixarene nanocapsule improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer Ther 2019; 18: 1497-1505.
31.
Saleem M, Abbas K, Manan M, Ijaz H, Ahmed B, Ali M, Hanif M, Farooqi AA, Qadir MI. Review-Epigenetic therapy for cancer. Pak J Pharm Sci 2015; 28: 1023-1032.
32.
Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O’Fallon J, Yates A, Feuerstein BG, Burger PC,Scheithauer BW, Jenkins RB. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999; 18: 4144-4152.
33.
Sousa F, Dhaliwal HK, Gattacceca F, Sarmento B, Amiji MM. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. J Control Release 2019; 309: 37-47.
34.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
35.
Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020; 70: 299-312.
36.
Tanriover G, Dilmac S, Aytac G, Farooqi AA, Sindel M. Effects of melatonin and doxorubicin on primary tumor and metastasis in breast cancer model. Anticancer Agents Med Chem 2022; 22: 1970-1983.
37.
Wang J, Liu Y, Morsch M, Lu Y, Shangguan P, Han L, Wang Z, Chen X, Song C, Liu S, Shi B, Tang BZ. Brain-targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics. Adv Mater 2022; 34: e2106082.
38.
Wang K, Kievit FM, Chiarelli PA, Stephen ZR, Lin G, Silber JR, Ellenbogen RG, Zhang M. siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model. Adv Funct Mater 2021; 31: 2007166.
39.
Yen CY, Huang HW, Shu CW, Hou MF, Yuan SS, Wang HR, Chang YT, Farooqi AA, Tang JY, Chang HW. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers. Cancer Lett 2016; 373: 185-192.
40.
Yenilmez EN, Genc D, Farooqi AA, Tunoglu S, Zeybek U, Akkoc T, Yaylim İ. Mesenchymal stem cells combined with IFNγ induce apoptosis of breast cancer cells partially through TRAIL. Anticancer Res 2020; 40: 5641-5647.
41.
Yu Y, Wang A, Wang S, Sun Y, Chu L, Zhou L, Yang X, Liu X, Sha C, Sun K, Xu L. Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study. Mol Pharm 2022; 19: 1219-1229.
